This market research study presents a detailed segmentation of the global deep brain stimulation (DBS) market by application (PD, dystonia, OCD, and epilepsy) and by geography (Americas, APAC, and EMEA). The leading vendors identified in this market are Boston Scientific, Medtronic, and St. Jude Medical.
Technavio’s market research analysts estimate the global DBS market to grow at a CAGR of more than 10% between 2016 and 2020. DBS system aka brain pacemaker, is primarily used to treat PD, essential tremor, OCD, and epilepsy. Being one of the latest evolving technologies in the neurostimulation, DBS market is expected to grow at a significant rate over the next four years owing to new product approvals, established reimbursement rates, especially in the US and Europe, and increased clinical evidence in terms of safety and efficacy. The Americas account for more than 65% of the global DBS market due to the presence of leading vendors in the US, which helps them focus and market their products in the region.
The new market research report from Technavio provides a breakdown and analysis of the DBS segments by technology.
“The emergence of hybrid neuroprosthetic devices is the latest trend being witnessed in the global DBS market. Manufacturers are increasingly focusing on combining neuroprosthetic technologies with pharmacological and electrical neuromodulation therapies for the brain, brainstem, and spinal cord to improve the recovery of motor functions. This device is known as a hybrid neuroprosthetic device which includes a catheter implanted in the brain tissue and a subcutaneously placed drug reservoir, which can be periodically refilled. This combination of two technologies can result in much efficient and effective treatment of neurological disease, thereby impelling this market’s growth over the predicted period,” says Barath Palada, Lead Analyst, Healthcare & Lifesciences, Technavio Research
Parkinson’s disease (PD) dominates the global DBS market and account for more than 76% of the overall market share. DBS system is implanted in patients whose PD symptoms like tremor, rigidity and stiffness cannot be treated with the help of medicines. In such cases, MRI scanning is done to identify the diseased area in the brain so the physicians can implant the electrodes that stimulate motor neuron. According to the Parkinson’s Disease Foundation, close to 10 million people have PD around the world which is expected to drive this market until the end of 2020.
The leading vendors in the global DBS market include Boston Scientific, Medtronic, and St. Jude Medical. The market is highly consolidated with three vendors holding most of the market share. Competition among vendors has spurred with the increase in the number of PD cases worldwide. The vendors in this market are focussing on advanced technologies, increasing product portfolio, and regulatory approval to compete in the market.
A more detailed analysis is available in the Technavio report Global DBS Market 2016-2020.
We can customize reports by other regions and specific segments upon request.
Other related reports:
